<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161506">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01980095</url>
  </required_header>
  <id_info>
    <org_study_id>RHB-105-01</org_study_id>
    <nct_id>NCT01980095</nct_id>
  </id_info>
  <brief_title>ERADICATE Hp - Treating Helicobacter Pylori With RHB-105</brief_title>
  <acronym>ERADICATE Hp</acronym>
  <official_title>A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RedHill Biopharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RedHill Biopharma Limited</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The &quot;test and treat&quot; strategy for treating dyspeptic patients who are H. pylori positive is
      rapidly becoming the standard of care.  This study will test the effectiveness of RHB-105, a
      new triple therapy to treat H. pylori infection in dyspeptic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a, randomized, double-blind, placebo-controlled study of RHB-105 in adult subjects
      complaining of epigastric discomfort that have been screened and found to be positive for H.
      pylori infection via 13C Urea Breath Test (UBT) and fecal antigen test.

      Eligible subjects will be randomized in a ratio of 1:2 between placebo arm (n=30) and the
      active arm (RHB-105) (n=60).  Subjects will receive study drug for 14 consecutive days.
      Eradication of H. pylori infection will be determined based on 13C UBT conducted between 28
      to 56 days after completion of study drug therapy.

      Subjects will be unblinded upon 13C UBT analysis.  This will provide timely active therapy
      to all subjects enrolled in this study. Subjects in the placebo arm will be entitled to
      receive standard-of-care as prescribed by the treating physician following un-blinding.

      Eradication failures (13C UBT-positive) in the active study drug arm will undergo upper
      endoscopy with sampling for culture and sensitivity testing (to rifabutin, amoxicillin,
      clarithromycin, and metronidazole). Culture and sensitivity directed therapy as prescribed
      by the treating physician will be offered to these subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The occurrence of H. pylori eradication as confirmed via 13C UBT testing</measure>
    <time_frame>28-56 days after completion of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - The occurrence and severity of adverse events during the study and changes from baseline in hematology and chemistry laboratory values.</measure>
    <time_frame>42 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the trough concentration of amoxicillin, omeprazole, rifabutin and rifabutin metabolite 25-O-desacetyl-rifabutin on Day 8</measure>
    <time_frame>8 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the trough concentration of amoxicillin, omeprazole, rifabutin and rifabutin metabolite 25-O-desacetyl-rifabutin on Day 15</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Severity of Dyspepsia Assessment (SODA)</measure>
    <time_frame>43-71 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient reported outcome - Severity of Dyspepsia Assessment (SODA) score prior to and after treatment with study drug</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacogenetic</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacogenetic - cytochrome P450 (CYP) 2C19 status</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Dyspepsia</condition>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>RHB-105</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RHB-105 is an 'all-in-one' combination oral capsule consisting of 2 different antibiotics and a proton pump inhibitor combined in a single capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsules that look like the RHB-105 product but contain no active ingredient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RHB-105</intervention_name>
    <description>The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:
Rifabutin 150 mg
Amoxicillin 3000 mg
Omeprazole 120 mg
Subjects will take study drug every 8 hours with food for 14 consecutive days.</description>
    <arm_group_label>RHB-105</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will take 4 placebo capsules every 8 hours with food for 14 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be ≥18 years of age and ≤ 65 years

          2. Have symptoms consistent with dyspepsia of at least two weeks duration (defined as
             recurrent pain or discomfort centered in the upper abdomen, often with a relation to
             meals)

          3. Be positive for H. pylori by 13C Urea Breath Test (UBT) and also by fecal antigen
             test

          4. Be informed of the nature of the study and provide written informed consent before
             any study specific procedures are performed (or have a legally authorized
             representative sign consent)

        Exclusion Criteria:

          1. Have alarm symptoms/signs (including unexplained anemia [iron deficiency), melena /
             hematemesis, anorexia, dysphagia, jaundice, weight loss)

          2. Have taken antibiotics in the 4 weeks prior to screening

          3. Have taken bismuth containing medications such as peptobismol in the 4 weeks prior to
             screening

          4. Have a history of any previous esophageal or gastric surgery, except for simple
             closure of perforated ulcer

          5. Have a history of gastric outlet obstruction

          6. Have a history of hypersecretory state such as Zollinger-Ellison Syndrome

          7. Have a history of gastric cancer

          8. Have the presence of active gastric and duodenal ulcers or presence of 3 or more
             active ulcers
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Y Graham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kirsten Jones, BSCR, CCRA</last_name>
    <phone>919-797-9482</phone>
    <email>kjones@clinipace.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kevin Watson, M.S.</last_name>
    <phone>949-224-2816</phone>
    <email>kwatson@clinipace.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Quiceno</last_name>
      <phone>714-774-7777</phone>
      <phone_ext>240</phone_ext>
      <email>rquiceno@act-trials.com</email>
    </contact>
    <investigator>
      <last_name>Michael DeMicco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute</name>
      <address>
        <city>Chino</city>
        <state>California</state>
        <zip>91710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joe Calleros</last_name>
      <phone>909-203-4707</phone>
      <email>jcalleros@catalinari.com</email>
    </contact>
    <investigator>
      <last_name>Gilbert Martinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jupiter Research, Inc.</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Goodwin, CCRC</last_name>
      <phone>561-743-4160</phone>
      <email>Cgoodwinjra@aol.com</email>
    </contact>
    <investigator>
      <last_name>Michael Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felicia Money</last_name>
      <phone>706-596-4894</phone>
      <email>fmoney@serrg.com</email>
    </contact>
    <investigator>
      <last_name>Michael Steinbook, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedPharmics</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Slocum</last_name>
      <phone>504-265-9951</phone>
      <email>timslocum@medpharmics.com</email>
    </contact>
    <investigator>
      <last_name>Robert Jeanfreau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peters Medical Research</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Meris</last_name>
      <phone>336-883-9773</phone>
      <email>wendym@petersmedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Lenin Peters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irfan Majeed</last_name>
      <phone>919-781-2514</phone>
      <email>imajeed@wakeresearch.com</email>
    </contact>
    <investigator>
      <last_name>Charles Barish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 18, 2013</lastchanged_date>
  <firstreceived_date>November 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>H. pylori</keyword>
  <keyword>Dyspepsia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
